NCT04536090View on ClinicalTrials.gov

Study of Isoquercetin (IQC-950AN) Plus Standard of Care Versus Standard of Care Only for the Treatment of COVID-19

PHASE2WithdrawnINTERVENTIONAL
0
Timeline

Start Date

January 31, 2022

Primary Completion Date

December 31, 2022

Study Completion Date

June 30, 2023

Conditions
COVID-19
Interventions
DRUG

Isoquercetin (IQC-950AN)

Isoquercetin will be administered by mouth twice daily for 28 days

Sponsors

Collaborators (1)

Pharmascience Inc.
All Listed Sponsors
collaborator

Pharmascience Inc.

INDUSTRY

collaborator

SCiAN Services, Inc.

UNKNOWN

collaborator

Quercis Pharma AG

INDUSTRY

lead

Institut de Recherches Cliniques de Montreal

OTHER